Generic of UCB allergy med Xyzal gets preliminary FDA approval for Synthon
Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal. Netherlands-based Synthon, which has its U.S. headquarters and laboratories in Research Triangle Park, North Carolina, said it is seeking to bring a generic version of Xyzal oral solution […]